Immune IQ
Develops an AI-driven platform to decode the human immune system for multi-disease detection at the point of care. The company is building a compact analyzer and low-cost disposable test cartridges combined with a centralized immune-dataset and automated machine-learning pipeline to enable early disease screening, clinical decision support, and expansion of diagnostic menus via partner apps and database-driven model training.
Industries
Nr. of Employees
small (1-50)
Products
Point-of-care immune-decoding diagnostic system
A compact analyzer paired with low-cost disposable cartridges and AI-driven analytics designed to scan immune-system signals for multiple diseases rapidly at the point of care.
Point-of-care immune-decoding diagnostic system
A compact analyzer paired with low-cost disposable cartridges and AI-driven analytics designed to scan immune-system signals for multiple diseases rapidly at the point of care.
Services
Design and conduct of clinical studies (hands-off and retrospective) to generate performance datasets for regulatory submissions and clinical evaluation.
Provision of aggregated immune-dataset and analytic tools to support partner model training, drug development, and companion diagnostic discovery.
Platform capability enabling in-house and third-party app development to expand the diagnostic test menu for the point-of-care platform.
Design and conduct of clinical studies (hands-off and retrospective) to generate performance datasets for regulatory submissions and clinical evaluation.
Provision of aggregated immune-dataset and analytic tools to support partner model training, drug development, and companion diagnostic discovery.
Platform capability enabling in-house and third-party app development to expand the diagnostic test menu for the point-of-care platform.
Expertise Areas
- AI-driven immune profiling
- Point-of-care diagnostic device development
- Disposable cartridge design and manufacturing
- Clinical performance evaluation and trial execution
Key Technologies
- Machine learning for immune-system signal decoding
- Microfluidics
- Tape-based disposable cartridge assembly
- Point-of-care analyzer hardware
News & Updates
Company states it holds approximately 100 patents related to its immune-decoding platform and technologies.
A month-long, hands-off clinical study at Massachusetts General Hospital demonstrated the system's ability to reliably generate its advanced dataset.
A preliminary clinical study reported superior results for COVID identification compared to PCR in the company’s dataset.
Company-reported dataset showed higher initial recognition of high-risk sepsis (94% vs. 30% cited) compared to the current process.
A retrospective study indicated the second-generation dataset had performance comparable to CT scan and cell-free DNA for lung cancer detection.
Company states it holds approximately 100 patents related to its immune-decoding platform and technologies.
A month-long, hands-off clinical study at Massachusetts General Hospital demonstrated the system's ability to reliably generate its advanced dataset.
A preliminary clinical study reported superior results for COVID identification compared to PCR in the company’s dataset.
Company-reported dataset showed higher initial recognition of high-risk sepsis (94% vs. 30% cited) compared to the current process.
A retrospective study indicated the second-generation dataset had performance comparable to CT scan and cell-free DNA for lung cancer detection.